Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The Hippo pathway represents a new opportunity for the treatment of cancer. Overexpression of Yes-associated protein (YAP) or transcriptional coactivator with PDZ-binding motif (TAZ) or TEAD has been demonstrated in cancers and YAP mediates resistance to cancer drugs. Since 2018, the potential of this pathway has been illustrated by numerous articles and patents and the first drugs entering in clinical trial phase 1. AREAS COVERED: This review is limited to published patent applications that have disclosed direct small-molecule inhibitors of the YAP/TAZ-TEAD interaction. EXPERT OPINION: The YAP/TAZ-TEAD transcriptional complex is a promising target for the treatment of cancer. Approximately 30 international patents (used database: Sci-finder, query: TEAD; documents: patents; period: from 2017-January 2022) that disclose TEAD transcriptional inhibitors have been filled since 2018. The mechanism of action is not always described in the patents, we can divide the drugs into three different categories: (i) external TEAD ligands; (ii) non-covalent TEAD ligands of the palmitate pocket; (iii) covalent TEAD ligands, which bind into the palmitate pocket. The first molecules in clinical trial phase 1 are non-covalent TEAD ligands. The selective TEAD ligand have also been patented, published and selectivity could be of great interest for personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · cited 1×
“Growing interest in the Hippo pathway has been firstly driven by its deregulation in many diverse cancers as reported in many reviews [2,3], then found interest in regenerative medicine [4–6] to finally emerge in the field of neurodegenerative diseases [7,8].”
BackgroundYAP1 increases organ size and expands undifferentiated progenitor cells
Camargo, F. D., Gokhale, S., Johnnidis, J. B., Fu, D., Bell, G. W., Jaenisch, R., & Brummelkamp, T. R. (2007) · Current Biology · doi:10.1016/j.cub.2007.10.039 · Cited by 1,252 · cited 1×
“and tumor formation resulting from transient activation of YAP is often reversible upon cessation of YAP activation [82,83].”
BackgroundHippo–YAP/TAZ signalling in organ regeneration and regenerative medicine
Moya, I. M., & Halder, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0086-y · Cited by 981
Justice, R. W., Zilian, O., Woods, D. F., Noll, M., & Bryant, P. J. (1995) · Genes & Development · doi:10.1101/gad.9.5.534 · Cited by 977 · cited 1×
“The highly conserved Hippo pathway, discovered in Drosophila in 1995, controls organ size and cell differentiation through the regulation of cell proliferation, apoptosis, and stem cell function [1].”
BackgroundTargeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860 · cited 1×
“Finally, Astra-Zeneca and academic laboratories reported TEAD ligands able to activate transcriptional activity of TEAD which could find interest in the field of regenerative medicine (cardiac regeneration, wound healing) [6] and neurodegenerative diseases [7].”
BackgroundKurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway
Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2036 · Cited by 313 · cited 2×
“in an internal hydrophobic pocket [16,17].”
BackgroundTang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J., Yu, F.-X., Guan, K.-L., & Post, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0717 · Cited by 245 · cited 3×
“Vivace Therapeutics reported the first selective TEAD1 ligand [50] and Genentech reported selective TEAD2/4 ligands that found great interest in specific TEAD deregulated cancers.”
BackgroundTGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth
Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111653 · Cited by 224
Research works printed but not linked: 49
- 10.1038/nrc3876 · DOI · Paper page
- 10.1038/nrd4161 · DOI · Paper page
- 10.1002/jnr.24551 · DOI · Paper page
- 10.3389/fnins.2020.00595 · DOI
- 10.1152/physrev.00005.2014 · DOI · Paper page
- 10.1016/j.cmet.2018.07.010 · DOI · Paper page
- 10.3389/fonc.2020.01266 · DOI
- 10.1101/gad.1865810 · DOI · Paper page
- 10.1002/cbic.201300163 · DOI · Paper page
- 10.1111/febs.14817 · DOI
- 10.1021/acs.jmedchem.7b00879 · DOI · Paper page
- 10.1016/j.str.2015.11.005 · DOI · Paper page
- 10.1002/jcc.20084 · DOI · Paper page
- Lam-Himlin DM, 2006, Int. J. Gastrointest. Cancer, 37, 103
- 10.1111/pcmr.12249 · DOI
- 10.3892/mmr.2014.2818 · DOI · Paper page
- 10.1038/nature25459 · DOI · Paper page
- 10.1016/j.bbagrm.2016.02.010 · DOI
- 10.3390/cancers10040090 · DOI
- 10.1080/13543776.2018.1549226 · DOI
- 10.1016/j.chembiol.2018.11.010 · DOI · Paper page
- 10.1016/j.ab.2019.113413 · DOI
- 10.1158/1535-7163.MCT-17-0560 · DOI · Paper page
- 10.1016/j.celrep.2020.107809 · DOI · Paper page
- 10.1016/j.bmcl.2019.06.022 · DOI
- 10.1021/acschembio.9b00786 · DOI
- 10.1016/j.ejmech.2021.113835 · DOI
- 10.1016/j.str.2015.09.009 · DOI · Paper page
- Kaneda A, 2020, Am J Cancer Res, 10, 4399
- 10.1021/acs.jmedchem.0c01275 · DOI
- 10.1016/j.ejmech.2019.111767 · DOI · Paper page
- 10.1371/journal.pone.0045498 · DOI
- 10.1038/sj.bjc.6604774 · DOI
- Joo JS, 2020, Oncol Rep, 43, 1785
- 10.1242/jcs.139865 · DOI · Paper page
- 10.1016/j.pan.2020.12.003 · DOI
- 10.1016/j.bbagrm.2016.02.010 · DOI
- 10.1038/onc.2015.342 · DOI
- 10.12998/wjcc.v7.i15.1954 · doi:10.12998/wjcc.v7.i15.1954
- Qi Y, 2016, Nat Commun, 7
- 10.1016/j.cell.2007.07.019 · DOI · Paper page
- 10.1016/j.ccell.2021.06.016 · DOI · Paper page
- 10.1080/23723556.2021.1981111 · DOI
- 10.1038/s41467-022-28691-0 · DOI · Paper page
- 10.1021/acs.jmedchem.2c00075 · DOI
- 10.1016/j.jid.2020.01.029 · DOI
- 10.1016/j.ajpath.2019.01.016 · DOI
- 10.18632/oncotarget.11057 · DOI
- 10.1158/0008-5472.CAN-13-2712 · DOI · Paper page
Cited by
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
TEAD Proteins Associate With DNA Repair Proteins to Facilitate Cellular Recovery From DNA Damage
Calses, P. C., Pham, V. C., Guarnaccia, A. D., Choi, M., Verschueren, E., Bakker, S. T., Pham, T. H., Hinkle, T., Liu, C., Chang, M. T., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100496 · Cited by 22
Metadata
- Authors
- Zagiel, B., Melnyk, P., & Cotelle, P.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2022-07-05
- Volume
- 32
- Issue
- 8
- Pages
- 899-912
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W4283735204
- Cited by
- 50
- References
- 13
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present). https://app.cochat.ai/papers/10.1080/13543776.2022.2096436
- The paper
- Zagiel, B., Melnyk, P., & Cotelle, P. (2022). Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2022.2096436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.